IVIG - BMC HealthNet Plan

43. Gamimune N, 10% [package insert]. Elkhart, IN: Bayer Corporation; October 2008.
44. Mouthon L, Lortholary O. Intravenous immunoglobulins in infectious diseases:
where do we stand Clin Microbiol Infect. 2003;9:333-338.
45. Centers for Disease Control and Prevention. Guidelines for prevention and treatment
of opportunistic infections in HIV-infected adults and adolescents. Recommendations
from CDC, the National Institutes of Health, and the HIV Medicine Association of
the Infectious Diseases Society of America. MMWR. 2009;58(No. RR-4):1-216.
46. American Academy of Pediatrics. Human Immunodeficiency Virus Infection. In:
Pickering LK, ed. Red Book Report of the Committee on Infectious Diseases. 287th
ed. Elk Grove Village, IL: American Academy of Pediatrics; 2009:380-400.
47. Mofenson LM, Brady MT, Danner S, et al; CDC; National Institutes of Health;
Infectious Diseases Society of America. Treating opportunistic infections among
HIV-exposed and infected children: recommendations from CDC, the National
Institutes of Health, The HIV Medicine Association of the Infectious Diseases
Society of America, the Pediatric Infectious Diseases Society of America and the
American Academy of Pediatrics. MMWR Recomm Rep. 2009;58(RR11);1-166.
Available at http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5811a1.htm. Accessed
12/8/09 01/11/11.
48. American Academy of Pediatrics. Active and Passive Immunization. In: Pickering
LK, ed. Red Book Report of the Committee on Infectious Diseases. 28th ed. Elk
Grove Village, IL: American Academy of Pediatrics; 2009;1(58):58-61.
49. [No authors listed]. Antiretroviral therapy and medical management of pediatric HIV
infection and 1997 USPHS/IDSA report on the prevention of opportunistic infections
in persons infected with human immunodeficiency virus. Pediatrics. 1998;102(4 Pt
2):999-1085.
50. Spector SA, Gelber RD, McGrath N, et al. A controlled trial of intravenous immune
globulin for the prevention of serious bacterial infections in children receiving
zidovudine for advanced human immunodeficiency virus infection. Pediatric AIDS
Clinical Trials Group. N Engl J Med. 1994;331:1181-1187.
51. Efthimiou P, Paik P, Bielory L. Diagnosis and management of adult onset Still's
disease. Ann Rheum Dis. 2006;65:564-572.
52. Enk A and the European Dermatology Forum Guideline Subcommittee. Guidelines
on the use of high-dose intravenous immunoglobulin in dermatology. Eur J
Dermatol. 2009;19:90-98.
53. Ahmed AR, Dahl MV. Consensus statement on the use of intravenous
immunoglobulin therapy in the treatment of autoimmune mucocutaneous blistering
diseases. Arch Dermatol. 2003;139:1051-1059.
54. Ruetter A, Luger TA. Efficacy and safety of intravenous immunoglobulin for
immune-mediated skin disease. Current view. Am J Clin Dermatol. 2004;5:153-160.
55. Ahmed AR. Use of intravenous immunoglobulin therapy in autoimmune blistering
diseases. Int Immunopharmacol. 2006;6:557-578.
56. Amagai M, Ikeda S, Shimizu H, et al. A randomized double-blind trial of intravenous
immunoglobulin for pemphigus. J Am Acad Dermatol. 2009;60(4);595-603.
This guideline provides information on BMC HealthNet Plan claims adjudication processing guidelines. The use of this
guideline is not a guarantee of payment and will not determine how a specific claim(s) will be paid. Reimbursement is
based on member benefits and eligibility, medical necessity review, where applicable, coordination of benefits, adherence
to Plan policies, clinical coding criteria, and the BMC HealthNet Plan agreement with the rendering or dispensing provider.
Reimbursement policies may be amended at BMC HealthNet Plan’s discretion. BMC HealthNet Plan will always use the
most recent CPT and HCPCS coding guidelines.
BMC HealthNet Plan – IVIG
36 of 45